US FDA Declines Novocure Device

The US Food and Drug Administration has declined to approve Novocure's device for lung cancer patients with brain metastases. The agency cited uncertainty regarding clinical benefit, though no safety concerns were raised.

Xurve View
Insights:
FILE PHOTO: Signage is seen outside of the Food and Drug Administration headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo

Novocure declined 12% on Monday after the United States Food and Drug Administration rejected its lung cancer therapy device. The regulatory setback halts commercial expansion plans for the company's flagship oncology portfolio. Investors now face delayed revenue streams as management weighs whether to launch expensive new clinical trials.